infliximab-abda Renflexis
Selected indexed studies
- Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. (Clin Pharmacokinet, 2018) [PMID:29330783]
- Efficacy and safety of infliximab in patients with autoimmune hepatitis. (Hepatology, 2025) [PMID:39250458]
- Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis. (Am J Ophthalmol, 2021) [PMID:32795432]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. (2018) pubmed
- Efficacy and safety of infliximab in patients with autoimmune hepatitis. (2025) pubmed
- SB2: An Infliximab Biosimilar. (2017) pubmed
- PF-06438179/GP1111: An Infliximab Biosimilar. (2018) pubmed
- Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC. (2026) pubmed
- Immunogenicity of infliximab and adalimumab. (2019) pubmed
- Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis. (2021) pubmed
- Comparing the Effectiveness and Safety Associated With Infliximab vs Infliximab-abda Therapy for Patients With Hidradenitis Suppurativa. (2021) pubmed
- Infusion-related angioedema associated with infliximab-abda: Case report. (2021) pubmed
- Inpatient Infliximab Biosimilar Cost-Savings: Cost Analysis of Inpatient Treatment with Originator Infliximab (Remicade™) versus Biosimilar Infliximab (Renflexis™) for Acute Severe Ulcerative Colitis. (2024) pubmed